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ABSTRACT
Aims: To examine the association of baseline
patient characteristics with study outcomes in
people with type 2 diabetes receiving insulin
glargine 300 U/mL (Gla-300) versus glargine
100 U/mL (Gla-100), over a 6-month period.
Methods: A post hoc patient-level meta-
analysis using data from three multicenter,
randomized, open-label, parallel-group, phase
3a studies of similar design, in people previously
receiving either basal and prandial insulin, basal
insulin ? oral antihyperglycemic drugs, or no
prior insulin (EDITION 1, 2 and 3, respectively).
The endpoints, glycated hemoglobin (HbA1c),
hypoglycemia, body weight change, and insulin
dose were investigated by subgroups: age (\ 65
and C 65 years), body mass index (BMI; \ 30
and C 30 kg/m2), age at onset (\40, 40–50, and
[ 50 years), and diabetes duration (\ 10 and
C 10 years).
Results: Reduction in HbA1c was comparable
between insulins, regardless of subgroup. The
lower risk of C 1 nocturnal (00:00–05:59 h)
confirmed (B 3.9 mmol/L [B 70 mg/dL]) or
severe hypoglycemic event with Gla-300 versus
Gla-100 was also unaffected by participant
characteristics. While heterogeneity of treat-
ment effect between diabetes duration sub-
groups was seen for the risk of C 1 confirmed
(B 3.9 mmol/L [B 70 mg/dL]) or severe hypo-
glycemic event at any time (24 h), treatment
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.701676.
Electronic Supplementary Material The online
version of this article (https://doi.org/10.1007/s13300-
018-0498-x) contains supplementary material, which is
available to authorized users.
S. M. Twigg (&)
University of Sydney, Sydney, Australia
e-mail: stephen.twigg@sydney.edu.au
J. Escalada
Clinic University of Navarra, Pamplona, Spain
J. Escalada
Biomedical Research Networking Center for
Physiopathology of Obesity and Nutrition
(CIBEROBN), Institute of Health Carlos III,
Pamplona, Spain
P. Stella  A. Merino-Trigo
Sanofi, Paris, France
F. J. Lavalle-Gonzalez
University Hospital, Universidad Auto´noma de
Nuevo Leo´n, San Nicola´s de los Garza, Mexico
B. Cariou
L’institut du thorax, CIC 1413 INSERM, CHU
Nantes, Nantes, France
L. F. Meneghini
University of Texas Southwestern Medical Center,
Dallas, TX, USA
L. F. Meneghini
Parkland Health & Hospital System, Dallas, TX, USA
Diabetes Ther (2018) 9:2043–2053
https://doi.org/10.1007/s13300-018-0498-x
effect consistently favored Gla-300; no evidence
of heterogeneity was observed for the
other subgroups. Annualized rates of confirmed
(B 3.9 mmol/L [B 70 mg/dL]) or severe hypo-
glycemia and body weight change were not
influenced by participant characteristics; a
similar pattern was observed with insulin dose.
Conclusions: Comparable glycemic control was
observed with Gla-300 versus Gla-100, with less
hypoglycemia, regardless of age, BMI, age at
onset or diabetes duration.
Funding: Sanofi.
Plain Language Summary: Plain language
summary available for this article.
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PLAIN LANGUAGE SUMMARY
Treatments for patients with type 2 diabetes aim
to reduce the levels of blood glucose and can
include injections with insulin. However, care
must be taken to prevent blood glucose levels
falling too low (a state called hypoglycemia).
Previous studies have shown that insulin glar-
gine 300 units/mL (Gla-300) provides similar
reductions in blood glucose levels as insulin
glargine 100 units/mL (Gla-100) but is less likely
to cause hypoglycemia. However, different
patients may respond differently to treatments
depending on their individual clinical and bio-
logical characteristics. The aim of this study was
to evaluate how different profiles of patients
with type 2 diabetes responded to Gla-300 and
Gla-100 injections. Patients were grouped by
different ages, weights, age at diabetes diagno-
sis, and number of years since diagnosis of dia-
betes. We found that Gla-300 and Gla-100
reduced glycated hemoglobin (HbA1c; a marker
of blood glucose control over the previous
2–3 months) similarly, regardless of how
patients were grouped. However, patients trea-
ted with Gla-300 were less likely to experience
hypoglycemia than those treated with Gla-100,
and this association was also true regardless of
different patient characteristics. We therefore
concluded that Gla-300 is an effective and safe
treatment in patients with type 2 diabetes,
regardless of their age, weight, age at diabetes
diagnosis, and years since diagnosis.
INTRODUCTION
Type 2 diabetes (Type 2 DM) is a heterogeneous
disease, with a population that exhibits diverse
clinical and biological characteristics [1, 2].
Current recommendations for the management
of Type 2 DM encourage a patient-centered
approach [3], such that less stringent glycemic
targets (e.g. glycated hemoglobin
[HbA1c]\64 mmol/mol [8.0%]) may be con-
sidered on an individual basis [4], to take into
account, for example, factors such as
polypharmacy, comorbidities, frailty, renal dis-
ease, and reduced life expectancy found to be
associated with increased risk of hypoglycemia.
To most appropriately individualize treatments
and glycemic targets, it is important to under-
stand how the characteristics of each individual
might affect the outcomes of treatment. Studies
investigating potential predictors of response
have highlighted several demographic and
clinical factors that may influence the effec-
tiveness of particular diabetes therapies, as well
as the attainment of glycemic targets [5–8].
Insulin glargine 300 U/mL (Gla-300;
Toujeo; Sanofi S.A., Paris, France) is a long-
acting basal insulin analog with prolonged and
more stable pharmacokinetic and pharmaco-
dynamic profiles than insulin glargine
100 U/mL (Gla-100; Lantus; Sanofi S.A.) [9].
The EDITION program included three multina-
tional clinical studies that compared the
efficacy and safety of Gla-300 to those of
Gla-100 in different populations of people
with Type 2 DM [10–12]. In the individual
EDITION studies and a post hoc, patient-level
meta-analysis, Gla-300 provided comparable
glycemic control to Gla-100 with fewer hypo-
glycemia events over 6 months of treatment
[10–13]. Change in body weight was low in both
treatment groups, with slightly less weight gain
in patients receiving Gla-300 [10–13].
The objective of the current post hoc analysis
was to investigate the potential association of
participant characteristics with key outcomes
reported from the EDITION 1–3 trials, in Type 2
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DM participants randomized to Gla-300 or
Gla-100. The characteristics chosen for this post
hoc analysis were those previously reported to
influence glycemic control in participants with
Type 2 DM [5–8]. For example, age, body
weight, and duration of diabetes have been
shown to be associated with change in HbA1c
[5]. Similarly, multivariate analyses in individ-
uals with Type 2 DM showed a higher success
rate of achieving glycemic control targets in
older participants, those with higher body mass
index (BMI), and those with a shorter duration
of diabetes [7]. In addition, older people with
Type 2 DM are at a greater risk of hypoglycemia
than are younger individuals [14]. In the cur-
rent analysis, glycemic control, hypoglycemia,
and body weight were assessed in subgroups of
participants defined by age, BMI, age at onset of
diabetes, and duration of diabetes, in a patient-
level meta-analysis of data from the three trials
over a 6-month period.
METHODS
Study Design
This post hoc analysis was performed on patient-
level data from the EDITION 1, EDITION 2, and
EDITION 3 studies. EDITION 1, 2, and 3 were
multicenter, randomized, open-label, two-arm,
parallel-group, phase 3a studies with 6-month
treatment periods (NCT01499082,
NCT01499095, and NCT01676220, respec-
tively), the study designs of which have been
described previously [10–12]. All participants
were C 18 years of age with a diagnosis of Type 2
DM (according to World Health Organization
criteria) [15], and prior to study enrolment they
were receiving either basal (C 42 units/day)
and prandial insulin therapy with or without
metformin for at least 1 year (EDITION 1) [10],
at least 6 months of basal insulin treatment
(C 42 units/day) in combination with oral anti-
hyperglycemic drugs (OADs) (EDITION 2) [11],
or at least 6 months of OADs and were insulin
naı¨ve (EDITION 3) [12]. In the EDITION 2 and 3
studies, participants discontinued the use of
sulphonylurea 2 months prior to screening and
at baseline, respectively. In all three studies,
participants were randomized (1:1) to receive
once-daily evening injections of either Gla-300
or Gla-100, and they were titrated to a fasting
self-monitored plasma glucose target of
4.4–5.6 mmol/L (80–100 mg/dL).
For the current analysis, the patient-level
dataset from EDITION 1, 2, and 3 was grouped
according to baseline: age (\65 and C 65 years),
BMI (\30 and C 30 kg/m2), age at onset of dia-
betes (\ 40, 40–50, and[50 years), and diabetes
duration (\ 10 and C 10 years). The cut-offs in
the age at onset analysis, which were not prede-
fined, were chosen to be clinically meaningful,
while limiting the difference in sample size
between subgroups.
Outcomes
The analysis was carried out for the following
endpoints, from baseline to treatment month 6:
change in HbA1c (%); number and percentage of
participants with at least one hypoglycemic
event, and annualized rates of hypoglycemia
(events per participant-year), both nocturnal
(00:00–05:59 h) and at any time of day (24 h),
and change in body weight. Daily basal insulin
dose and change in dose from baseline to treat-
ment month 6 was also reported by subgroup.
Hypoglycemia was defined as confirmed
(B 3.9 mmol/L [B 70 mg/dL]) or severe, or as
documented symptomatic (B 3.9 mmol/L
[B 70 mg/dL]), based on American Diabetes Asso-
ciation (ADA) categories described at the time
when the EDITION studies were undertaken [16].
The confirmed or severe definition of hypo-
glycemia combined three ADA categories: docu-
mented symptomatic hypoglycemia,
asymptomatic hypoglycemia, and severe
hypoglycemia.
Data Analysis and Statistics
For each endpoint considered, differences of
treatment effect across subgroups were assessed
with a heterogeneity test. Differences of treat-
ment effect across subgroups were only consid-
ered to be relevant if evidence of heterogeneity
was observed (p\ 0.05). The p values of
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the heterogeneity test were generated using a
subgroup-by-treatment interaction.
Change in HbA1c was analyzed using a mixed
model for repeated measurements. The per-
centage of participants with at least one hypo-
glycemic event was analyzed using the
Cochran–Mantel–Haenszel method, and annu-
alized rates of hypoglycemia (events per
participant-year) were analyzed using an over-
dispersed Poisson regression model. Change in
body weight was assessed using an analysis of
covariance model (ANCOVA), from baseline to
last on-treatment value. Daily basal insulin dose
was assessed using descriptive statistics.
Compliance with Ethics Guidelines
All procedures performed in studies involving
human participants were in accordance with
the ethical standards of the appropriate local or
national research committees and with the
1964 Helsinki declaration and its later amend-
ments or comparable ethical standards.
Informed consent was obtained from all indi-
vidual participants included in the study.
RESULTS
Baseline Characteristics
In total, 2496 participants were included in this
patient-level meta-analysis of the three
EDITION Type 2 DM studies, of whom 1247
were randomized to Gla-300 and 1249 were
randomized to Gla-100. Baseline characteristics
of this study population have been reported
previously [13] and are summarized together
with the age at onset of diabetes in Table 1. Mean
age, BMI, age at onset of diabetes, and diabetes
duration were similar in both treatment arms.
Glycemic Control
Reduction in HbA1c over the 6-month study
period was comparable between the Gla-300
and Gla-100 treatment arms, regardless of age,
BMI, age at onset of diabetes, or diabetes dura-
tion (Fig. 1). These findings were consistent
with the overall pooled study population. No
evidence of heterogeneity of treatment effect
across subgroups was observed over the
6-month treatment period (p[0.05).
Hypoglycemia
The lower risk of nocturnal (00:00–05:59 h)
confirmed (B 3.9 mmol/L [B 70 mg/dL]) or
severe hypoglycemia with Gla-300 versus Gla-
100 seen in the overall pooled study population
was not affected by age, BMI, age at onset of
diabetes, or diabetes duration, as no evidence of
heterogeneity of treatment effect across sub-
groups was seen over the 6-month treatment
period (p[0.05; Fig. 2a). Similarly, the lower
risk of confirmed (B 3.9 mmol/L [B 70 mg/dL])
or severe hypoglycemia at any time of day
Table 1 Baseline characteristics of the population with
type 2 diabetes included in this patient-level meta-analysis
of the EDITION 1, 2, and 3 studies (randomized
population)
Baseline
characteristics
Gla-300
(n = 1247)
Gla-100
(n = 1249)
Age, years 58.7 ± 9.3 58.5 ± 9.5
Gender (male), n (%) 657 (52.7) 649 (52.0)
Ethnic group, n (%)
Caucasian 1096 (87.9) 1095 (87.7)
Black 90 (7.2) 94 (7.5)
Asian 48 (3.8) 49 (3.9)
Other 13 (1.0) 11 (0.9)
BMI, kg/m2 34.7 ± 6.9 34.8 ± 6.4
Age at onset of
diabetes, years
46.5 ± 9.6 46.4 ± 9.9
Duration of
diabetes, years
12.7 ± 7.2 12.6 ± 7.5
HbA1c,
mmol/mol (%)
67 (8.31 ± 0.92) 67 (8.32 ± 0.91)
BMI Body mass index, HbA1c glycated hemoglobin
Values are presented as the mean ± standard deviation
unless otherwise stated. Age, BMI, duration of diabetes,
gender, and HbA1c have been published previously [13]
2046 Diabetes Ther (2018) 9:2043–2053
(24 h) with Gla-300 versus Gla-100 was not
affected by age, BMI, or age at onset of diabetes
(no evidence of heterogeneity of treatment
effect across subgroups: p[ 0.05; Fig. 2b). For
the diabetes duration subgroup analysis, some
degree of heterogeneity of treatment effect was
observed between participants with a diabetes
duration of\ 10 years and those with a diabetes
duration of C 10 years (p = 0.006), although the
treatment benefit was consistently in favor of
Gla-300 regardless of diabetes duration (Fig. 2b).
Whenconfirmed(B 3.9 mmol/L [B 70 mg/dL])
or severe hypoglycemic events were considered
in terms of annualized rates (events per partici-
pant-year), no evidence of heterogeneity of
treatment effect was observed across any sub-
groups, either at night (00:00–05:59 h) or at any
time of day (24 h) (p[0.05; Fig. 3a, b).
Similar findings were observed for documented
symptomatic (B 3.9 mmol/L [B 70 mg/dL])
hypoglycemia, both in terms of relative risk and
rate ratios; however, some degree of heterogene-
ity of treatment effect was observed for annual-
ized rates at any time of day (24 h) between
participants with a BMI of\30 kg/m2 and those
with a BMI of C 30 kg/m2 (p = 0.037; Electronic
Supplementary Material ([ESM] Figs. S1–2).
The risk of at least one severe hypoglycemic
event at any time of day (24 h) was comparable
between the Gla-300 and Gla-100 treatment
arms, regardless of age, BMI, age at onset of
diabetes, or diabetes duration (ESM Fig. S3). No
evidence of heterogeneity of treatment effect
across subgroups was observed for all subgroups
(ESM Fig. S3).
Body Weight
Over the 6-month treatment period, change in
body weight was comparable between sub-
groups, with a trend for slightly less weight gain
in those patients on Gla-300 compared with
those on Gla-100 (Table 2). No evidence of
heterogeneity of treatment effect was observed
in the age, BMI, age at onset of diabetes, or
diabetes duration subgroups (p = 0.486, 0.942,
0.566, 0.663, respectively).
Insulin Dose
Daily basal insulin dose increased over the
6-month treatment period in both treatment
groups, with a slightly higher dose (10–16%) at
−0.3 −0.2 −0.1 0.0 0.1 0.2 0.3
Overall 2474 −0.00 (−0.08 to 0.07) −
mITT (n)
Age <65 years
≥65 years
1819
655
−0.00 (−0.09 to 0.08)
 0.00 (−0.14 to 0.15) 0.954
<30 kg/m2
≥30 kg/m2
617
1857
0.03 (−0.12 to 0.17)
−0.01 (−0.10 to 0.07) 0.665
BMI
<40 years
40−50 years
>50 years
617
950
899
0.04 (−0.110 to 0.184)
0.02 (−0.094 to 0.142)
−0.05 (−0.177 to 0.068)
0.555
Age at onset 
of diabetes
<10 years
≥10 years
970
1496
−0.09 (−0.21 to 0.03)
 0.05 (−0.04 to 0.15) 0.067
Diabetes 
duration*
LS mean difference
Gla-300 vs Gla-100
(95% CI)
Heterogeneity of
treatment effect 
across subgroups
p-value
Favors
Gla-100
Favors
Gla-300
Fig. 1 Reduction in glycated hemoglobin (HbA1c [%]) in
people with type 2 diabetes (Type 2 DM) over 6 months
of treatment by subgroup (mITT population; pooled data
from EDITION 1, 2 and 3). *Diabetes duration not
available for 8 participants. BMI Body mass index,
CI confidence interval, Gla-300/Gla-100 insulin glargine
300 units/mL/insulin glargine 100 units/mL, LS least
squares, mITT modified intent-to-treat
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treatment month 6 for Gla-300 compared with
Gla-100 in each of the subgroups (ESM
Table S1). The treatment difference in change
from baseline to month 6 was generally com-
parable across the subgroups (ESM Table S1).
Overall 2488 0.75 (0.68 to 0.83) −
Safety 
population
(n)
Age <65 years
≥65 years
1829
659
0.77 (0.68 to 0.87)
0.70 (0.57 to 0.85) 0.366
<30 kg/m2
≥30 kg/m2
619
1869
0.73 (0.59 to 0.91)
0.75 (0.67 to 0.85) 0.774
BMI
<40 years
40−50 years
>50 years
622
954
904
0.65 (0.54 to 0.79)
0.80 (0.69 to 0.94)
0.77 (0.63 to 0.94)
0.172
Age at onset 
of diabetes
<10 years
≥10 years
980
1500
30.0
Gla-300
(% participants)
29.3
31.8
29.7
30.1
31.1
33.8
25.1
21.8
34.9
39.8
Gla-100
(% participants)
38.0
44.9
40.4
39.6
47.9
40.6
33.1
26.3
48.9
0.81 (0.65 to 1.01)
0.73 (0.64 to 0.82) 0.109
Diabetes 
duration*
RR
Gla-300 vs
Gla-100
(95% CI)
Heterogeneity
of treatment
effect 
across
subgroups
p-value
RR (95% CI)
1.41.00.80.6 1.20.4
Favors
Gla-100
Favors
Gla-300
(a)
(b)
Favors
Gla-100
Favors
Gla-300
−)69.0 ot 78.0( 19.08842llarevO
Safety 
population
(n)
Age <65 years
≥65 years
1829
659
0.90 (0.85 to 0.96)
0.93 (0.85 to 1.01) 0.927
<30 kg/m2
≥30 kg/m2
619
1869
0.89 (0.81 to 0.98)
0.91 (0.86 to 0.96) 0.654
BMI
<40 years
40−50 years
>50 years
622
954
904
0.86 (0.79 to 0.95)
0.91 (0.84 to 0.98)
0.94 (0.86 to 1.03)
0.306
Age at onset 
of diabetes
<10 years
≥10 years
980
1500
65.5
Gla-300
(% participants)
63.4
71.6
66.7
65.1
65.7
67.1
63.9
55.0
72.2
72.0
Gla-100
(% participants)
70.0
77.4
74.7
71.2
75.9
72.9
68.3
56.6
82.5
0.96 (0.86 to 1.07)
0.88 (0.84 to 0.93) 0.006
Diabetes 
duration*
RR
Gla-300 vs
Gla-100
(95% CI)
Heterogeneity
of treatment
effect 
across
subgroups
p-value
RR (95% CI)
1.41.00.80.6 1.20.4
Fig. 2 Relative risk (RR) of experiencing confirmed
(B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemia
during the night (00:00–05:59 h) (a) and at any time of
day (24 h) (b), over 6 months of treatment by subgroup
(% participants with C 1 event; safety population; pooled
data from EDITION 1, 2, and 3). *Diabetes duration not
available for 8 participants
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DISCUSSION
Guidelines for the management of Type 2 DM
recommend a patient-centered approach that
considers the needs and preferences of each
individual [3]. The outcomes of diabetes treat-
ment can differ depending on an individual’s
characteristics [5–7, 17]. The objective of this
0.8
Favors
Gla-100
Favors
Gla-300
Overall 2488 0.69 (0.57 to 0.84) −
Safety 
population
(n)
Age <65 years
≥65 years
1829
659
0.72 (0.57 to 0.91)
0.62 (0.43 to 0.89) 0.492
<30 kg/m2
≥30 kg/m2
619
1869
0.79 (0.57 to 1.09)
0.63 (0.50 to 0.79) 0.259
BMI
<40 years
40−50 years
>50 years
622
954
904
0.64 (0.45 to 0.92)
0.69 (0.51 to 0.93)
0.75 (0.53 to 1.08)
0.822
Age at onset 
of diabetes
<10 years
≥10 years
980
1500
2.10
Gla-300
(Events per 
participant-year)
2.06
2.23
2.93
1.81
2.34
2.29
1.76
1.49
2.49
3.06
Gla-100
(Events per 
participant-year)
2.86
3.63
3.64
2.89
3.64
3.28
2.41
1.89
3.87
0.79 (0.54 to 1.16)
0.66 (0.52 to 0.82) 0.415
Diabetes 
duration*
RR
Gla-300 vs
Gla-100
(95% CI)
Heterogeneity
of treatment
effect 
across
subgroups
p-value
(a)
0.4 1.41.00.6 1.2
RR (95% CI)
Favors
Gla-100
Favors
Gla-300
Overall 2488 0.86 (0.77 to 0.97) −
Safety 
population
(n)
Age <65 years
≥65 years
1829
659
0.87 (0.75 to 1.00)
0.85 (0.69 to 1.05) 0.877
<30 kg/m2
≥30 kg/m2
619
1869
0.75 (0.60 to 0.95)
0.89 (0.78 to 1.02) 0.218
BMI
<40 years
40−50 years
>50 years
622
954
904
0.71 (0.57 to 0.88)
0.95 (0.80 to 1.14)
0.91 (0.73 to 1.13)
0.107
Age at onset 
of diabetes
<10 years
≥10 years
980
1500
15.22
Gla-300
(Events per 
participant-year)
14.24
18.04
15.24
15.21
16.18
17.55
12.36
10.23
18.37
17.73
Gla-100
(Events per 
participant-year)
16.47
21.25
19.76
17.11
22.87
17.82
14.04
10.76
22.35
0.94 (0.75 to 1.19)
0.83 (0.73 to 0.95) 0.364
Diabetes 
duration*
RR
Gla-300 vs
Gla-100
(95% CI)
Heterogeneity
of treatment
effect 
across
subgroups
p-value
(b)
RR (95% CI)
0.4 1.41.00.80.6 1.2
Fig. 3 Annualized rates of confirmed (B 3.9 mmol/L
[B 70 mg/dL]) or severe hypoglycemia during the night
(00:00–05:59 h) (a) and at any time of day (24 h) (b), over
6 months of treatment by subgroup (events per
participant-year; safety population; pooled data from
EDITION 1, 2, and 3). *Diabetes duration not available
for 8 participants. RR rate ratio
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post hoc analysis of the EDITION studies was to
examine the association between participant
characteristics and study outcomes in people
with Type 2 DM receiving Gla-300 versus
Gla-100. Glycemic control was comparable
between the treatment groups, as expected in
a ‘treat-to-target’ study, but there was less
nocturnal hypoglycemia in patients on Gla-300
than in those on Gla-100 regardless of partici-
pant age, BMI, age at onset of diabetes, or
duration of diabetes. The benefits of Gla-300
observed across these subgroups were consistent
with those observed in the overall pooled study
population.
The heterogeneity of treatment effect
observed across the diabetes duration subgroups
(for risk of hypoglycemia at any time of day
[24 h]) suggests that Gla-300 may be particu-
larly beneficial in reducing hypoglycemia in
people with a longer duration of diabetes
(C 10 years) compared with Gla-100. However,
these findings may have been driven by differ-
ences in the study populations reflecting the
individual study inclusion criteria. Participants
with a diabetes duration of\ 10 years are most
likely to have been from the EDITION 3 study,
which enrolled insulin-naı¨ve people with a
mean diabetes duration of 10 years [12]. In
contrast, the mean durations of diabetes in
EDITION 1 and EDITION 2 were 16 years and
13 years, respectively [10, 11]. Other differences
between the individual study populations could
also have affected these findings; for example,
the use of mealtime insulin in EDITION 1,
which would have been overrepresented in
the C 10 years diabetes duration group, may
have impacted hypoglycemia occurring during
the day. However, it is interesting to note that
there was a trend towards heterogeneity of
treatment effect across the diabetes duration
Table 2 Change in body weight (kg) over the 6-month treatment period in patient-level meta-analysis of the EDITION 1,
2 and 3 studies (safety population)
Patient
parameters
Safety
population
(n)
LS mean difference in change
from baseline to last on-treatment
value: Gla-300 vs Gla-100 (95% CI)a
Heterogeneity of
treatment effect across
subgroups p value
Age, years
\ 65 1829 - 0.34 (- 0.65 to - 0.03) 0.486
C 65 659 - 0.12 (- 0.64 to 0.40)
BMI, kg/m2
\ 30 619 - 0.31 (- 0.84 to 0.23) 0.942
C 30 1869 - 0.28 (- 0.59 to 0.02)
Age at onset of diabetes, years
\ 40 607 - 0.50 (- 1.04 to 0.03) 0.566
40–50 938 - 0.14 (- 0.57 and 0.29)
[ 50 879 - 0.24 (- 0.68 and 0.21)
Diabetes duration, years
\ 10 980 - 0.19 (- 0.62 to 0.24) 0.663
C 10 1500 - 0.31 (- 0.66 to 0.03)
CI confidence interval, LS least squares
a Last on-treatment value was defined as the value collected at or just prior to the last investigational product intake during
the main treatment. Based on meta-analysis of the endpoint with subgroup and subgroup-by-treatment interactions as fixed
effects
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subgroups for change in HbA1c. It is therefore
possible that the heterogeneity between the
diabetes duration subgroups was due to a dif-
ference in treatment approaches in the two
subgroups of participants—as those with a
longer duration of diabetes are a more complex
population and more likely to have a greater
pharmacological treatment burden at baseline
and an increased risk of hypoglycemia—rather
than simply a difference between the treat-
ments used.
Although a heterogeneity of treatment effect
was observed between BMI subgroups for
annualized rates of documented symptomatic
(B 3.9 mmol/L [B 70 mg/dL]) hypoglycemia at
any time of day (24 h), the benefit of Gla-300
versus Gla-100 (in terms of direction of effect)
was apparent in both BMI subgroups.
An earlier age at onset of diabetes has also
been associated with higher HbA1c [8], as well as
being linked to a greater risk of diabetes com-
plications, such as diabetic retinopathy and
more severe albuminuria, in people with Type 2
DM [18, 19]. In the current analysis, those with
an earlier age at onset showed a trend towards
having higher baseline BMI and body weight
(ESM Table S2), which may suggest a specific
phenotype for this subgroup; however, this may
be expected based on the pathophysiology of
diabetes, and further analysis is required to
confirm this.
There was a trend for lower weight gain in
patients on Gla-300 compared with those on
Gla-100, as observed in the EDITION studies
[10, 12, 13, 20], and no evidence of hetero-
geneity of treatment effect across the subgroups
of participant characteristics was observed. As
also previously observed in the EDITION studies
[10, 12, 13, 20], a slightly higher mean basal
insulin dose was seen at month 6 with Gla-300
compared with Gla-100. In the current analysis,
insulin dose profiles appeared to be unaffected
by participant characteristics, although this
parameter was not assessed statistically.
The limitations of this study include the post
hoc exploratory nature of the analysis. An
imbalance in the number of participants across
the subgroups may have introduced some bias
within the analysis. Nevertheless, the cut-offs
chosen are meant to demonstrate the lack of
association between these participant charac-
teristics and treatment outcomes with Gla-300
versus Gla-100. Furthermore, the age cut-off
(C 65 years) is aligned with that used through-
out the ADA guidelines for the treatment of
older people with diabetes [21]. In addition,
other imbalances between subgroups may have
affected the results. For example, the age at
onset of diabetes subgroup of partici-
pants\40 years had a higher proportion of
individuals from the EDITION 1 study than did
the other studies. However, it should be noted
that the cut-offs for the age at onset of diabetes
subgroup were chosen to ensure a comparable
number of participants in each subgroup.
Finally, EDITION 3 contributed a greater pro-
portion of participants to the subgroup
BMI\30 kg/m2 than did EDITION 1 and 2.
These imbalances could have potentially
impacted the results of risk/rates of hypo-
glycemia at any time of day, due to the use of
prandial insulin therapy.
An individual’s characteristics may also
influence the effectiveness of specific therapies;
for example, metformin has been shown to be
less effective than intensive lifestyle changes in
people with low BMI and in older people
[22, 23]. Given the potential impact on
response to therapy, the profile of an individual
can influence clinical decisions relating to dis-
ease management and treatment at the indi-
vidual level. When considering initiating or
switching to basal insulin therapy with Gla-300,
it is reassuring that in this analysis the benefits
of Gla-300 were consistent regardless of sub-
group, suggesting that age, BMI, age at onset of
diabetes, and diabetes duration are not impor-
tant influencing factors for such treatment
decisions.
CONCLUSION
The comparable glycemic control of Gla-300
versus Gla-100 with less hypoglycemia seen in
the EDITION studies of people with Type 2 DM
was observed irrespective of participant age,
BMI, age at onset of diabetes, or duration of
diabetes in this analysis.
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